Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma

This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo-HCT) platforms in patients with adult T-cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)-haploidentical-related donors using post-transplant cyclophosphamide (PTCY), HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo-HCT between 2016 and 2021 were included. Outcomes analysed were overall survival (OS), relapse and non-relapse mortality (NRM). Seven hundred patients were included (PTCY, n = 121; MRD, n = 91; MUD, n = 160; CBT, n = 328). With a median follow-up of 794 days for survivors, 2-year OS was 48.1% (PTCY), 48.8% (MRD), 48.4% (MUD) and 34.6% (CBT); the respective 2-year cumulative incidence of relapse was 37.1%, 47.5%, 33.9% and 45.1% and that of NRM was 24.2%, 19.8%, 24.7% and 27.3%. PTCY was associated with delayed platelet engraftment relative to MRD and MUD. There was no increase in the incidence of severe acute or chronic graft-versus-host disease. In the PTCY group, poor performance status was a significant predictor of inferior OS, and infused CD34+ cell numbers of less than 5 × 10<sup>6</sup>/kg were associated with delayed neutrophil and platelet engraftment. These results suggest that allo-HCT with PTCY is a safe and effective platform for patients with adult T-cell leukaemia/lymphoma.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2024-10-19
DOI
https://doi.org/10.1111/bjh.19835
Citations
9
Primary Topic
T-cell and Retrovirus Studies
Type
article
Field-Weighted Citation Impact
2.16

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma

Masatsugu Tanaka, Hidehiro Itonaga, Naoyuki Uchida, Yoshinobu Kanda et al.
9 citations
British Journal of Haematology
T-cell and Retrovirus Studies
2.16
article

Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post‐transplantation cyclophosphamide for adult T‐cell leukaemia/lymphoma

Masatsugu Tanaka, Hidehiro Itonaga, Naoyuki Uchida, Yoshinobu Kanda, Keiichi Akizuki, Satoko Morishima, Koji Kato, Nobuaki Nakano, Yoshiko Atsuta, Toshiro Kawakita, Shuichi Ota, Kenji Ishitsuka, Shigeo Fuji, Tetsuya Eto, Makoto Yoshimitsu, Jun Ishikawa, Hiroyuki Muranushi, Ayumu Ito, Takashi Tanaka, Masahito Tokunaga, Takahiro Fukuda, Toshihiko Ando, Hiroyuki Ohigashi
article en
9 citations

Abstract

This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo-HCT) platforms in patients with adult T-cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)-haploidentical-related donors using post-transplant cyclophosphamide (PTCY), HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo-HCT between 2016 and 2021 were included. Outcomes analysed were overall survival (OS), relapse and non-relapse mortality (NRM). Seven hundred patients were included (PTCY, n = 121; MRD, n = 91; MUD, n = 160; CBT, n = 328). With a median follow-up of 794 days for survivors, 2-year OS was 48.1% (PTCY), 48.8% (MRD), 48.4% (MUD) and 34.6% (CBT); the respective 2-year cumulative incidence of relapse was 37.1%, 47.5%, 33.9% and 45.1% and that of NRM was 24.2%, 19.8%, 24.7% and 27.3%. PTCY was associated with delayed platelet engraftment relative to MRD and MUD. There was no increase in the incidence of severe acute or chronic graft-versus-host disease. In the PTCY group, poor performance status was a significant predictor of inferior OS, and infused CD34+ cell numbers of less than 5 × 10<sup>6</sup>/kg were associated with delayed neutrophil and platelet engraftment. These results suggest that allo-HCT with PTCY is a safe and effective platform for patients with adult T-cell leukaemia/lymphoma.

British Journal of HaematologyVol. 206(1)
Kagoshima University (JP), University of Miyazaki (JP), Kyushu University (JP), Jichi Medical University (JP), Aichi Medical University (JP), Saga University (JP), Kanagawa Prefectural Hospital Organization (JP), University of the Ryukyus (JP), Kurashiki Central Hospital (JP), Hamanomachi Hospital (JP), Sapporo Hokuyu Hospital (JP), Imamura Hospital (JP), Hokkaido University Hospital (JP), Osaka International Cancer Institute (JP), The Japanese Data Center for Hematopoietic Cell Transplantation (JP), Nagasaki University Hospital (JP), Kumamoto Medical Center (JP), Toranomon Hospital (JP), Kanagawa Cancer Center
Japan Agency for Medical Research and Development, Eisai, Chugai Pharmaceutical, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 12%
T-cell and Retrovirus Studies
2.16
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.